Literature DB >> 29322894

Patient restrictions following total hip arthroplasty: A national survey.

A Peters, A J H Veldhuijzen, M Tijink, R W Poolman, R M H A Huis In 't Veld.   

Abstract

In this prospective nation-wide web based survey we describe the current practice regarding patient restrictions following total hip arthroplasty. A web-based survey involving 20 items was developed and tested prior to administration. The questionnaire included general information, type of restrictions, specification and duration of restrictions. The target population consisted of all orthopaedic surgeons registered with the Dutch Orthopaedic Association working at one of the 94 orthopaedic departments in the Netherlands. The response rate of the orthopaedic departments was 78% (n=74). The majority of orthopaedic departments use patient restrictions following THA. Restrictions were used with different rates per type of surgical approach: anterior (69%), anterolateral (100%), straight lateral (94%) and posterolateral (93%). The duration of these restrictions is generally six weeks. Patient restrictions following THA are current practice, regardless of the surgical approach.

Entities:  

Mesh:

Year:  2017        PMID: 29322894

Source DB:  PubMed          Journal:  Acta Orthop Belg        ISSN: 0001-6462            Impact factor:   0.500


  2 in total

1.  Varying but reduced use of postoperative mobilization restrictions after primary total hip arthroplasty in Nordic countries: a questionnaire-based study.

Authors:  Kirill Gromov; Anders Troelsen; Maziar Modaddes; Ola Rolfson; Ove Furnes; Geir Hallan; Antti Eskelinen; Perttu Neuvonen; Henrik Husted
Journal:  Acta Orthop       Date:  2019-02-11       Impact factor: 3.717

2.  Risk Factors for Revision After Early and Delayed Total Hip Arthroplasty Dislocation. An Analysis of Lithuanian Arthroplasty Register.

Authors:  Povilas Masionis; Tomas P Vileikis; Giedrius Kvederas; Valentinas Uvarovas; Igoris Šatkauskas; Tomas Sveikata; Jaunius Kurtinaitis
Journal:  Cureus       Date:  2021-03-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.